Abstract
We compared the prevalence of serum hepatitis B virus (HBV) DNA in cancer patients who were immunocompromised with that in healthy subjects. Testing positive for serum HBV DNA were 27 of the 232 (11.6%) surface-antigen-negative cancer patients and 7 of the 382 (1.8%) surface-antigen-negative healthy subjects. These data suggest that the negative serology, at least in immunocompromised individuals, is probably not sufficient to exclude HBV infection.
Original language | English |
---|---|
Pages (from-to) | 449-451 |
Number of pages | 3 |
Journal | Journal of Clinical Microbiology |
Volume | 25 |
Issue number | 2 |
DOIs | |
State | Published - 1987 |